Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer

Journal of Medical Imaging and Radiation Oncology

Volumn 58, Issue 2, 2014, Pages 223-228

  Chang, David ^a   Joseph, David J ^b,c,e   Ebert, Martin A ^b,c   Galvão, Daniel A ^e   Taaffe, Dennis R ^e,f,h   Denham, James W ^g   Newton, Robert U ^e   Spry, Nigel A ^b,d,e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e EDITH COWAN UNIVERSITY   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CT; intramuscular fat; myosteatosis; sarcopenia.

Indexed keywords

LEUPRORELIN; ZOLEDRONIC ACID; ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MUSCLE ATTENUATION; MUSCLE MASS; MUSCLE STRENGTH; MUSCULOSKELETAL SYSTEM PARAMETERS; PRIORITY JOURNAL; PROSTATE CANCER; QUADRICEPS FEMORIS MUSCLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUS FEMORIS MUSCLE; SARTORIUS MUSCLE; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED; MUSCLE ATROPHY; PROSTATIC NEOPLASMS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SKELETAL MUSCLE; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84897579615     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12124     Document Type: Article

References (30)

1. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827.
2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-106.
3. Kaisary AV,. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 140-151.
4. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244.
5. Galvao DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44-47.
6. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-588.
7. Galvao DA, Taaffe DR, Spry N, et al. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 2009; 12: 198-203.
8. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.
9. Spry NA, Taaffe DR, England PJ, et al. Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study. Prostate Cancer Prostatic Dis 2013; 16: 67-72.
10. Spry NA, Kristjanson L, Hooton B, et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42: 1083-1092.
11. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of the 'androgen deprivation syndrome' in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166: 465-471.
12. Taaffe DR, Henwood TR, Nalls MA, et al. Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology 2009; 55: 217-223.
13. Goodpaster BH, Kelley DE, Thaete FL, et al. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 2000; 89: 104-110.
14. Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: the Health ABC Study. J Appl Physiol 2001; 90: 2157-2165.
15. Visser M, Goodpaster BH, Kritchevsky SB, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005; 60: 324-333.
16. National Electrical Manufacturers Association. Digital Imaging and Communications in Medicine (DICOM) Standard. 2010. [Cited 19 July 2011.] Available from URL: http://medical.nema.org/
17. Baxter BS, Hitchner LE, Maguire GQ Jr,. A standard format for digital image exchange. American Association of Physics in Medicine; 1982. [Cited 2010 Aug 8]. Available from URL: http://www.aapm.org/pubs/reports/rpt-10.pdf
18. Ebert MA, Haworth A, Kearvell R, et al. Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. Radiother Oncol 2008; 86: 200-210.
19. Taaffe DR, Sipila S, Cheng S, et al. The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention. Clin Physiol Funct Imaging 2005; 25: 297-304.
20. Larson-Meyer DE, Smith SR, Heilbronn LK, et al. Muscle-associated triglyceride measured by computed tomography and magnetic resonance spectroscopy. Obesity (Silver Spring) 2006; 14: 73-87.
21. Lang T, Cauley JA, Tylavsky F, et al. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res 2010; 25: 513-519.
22. Goodpaster BH, Thaete FL, Simoneau JA, et al. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579-1585.
23. Torriani M, Hadigan C, Jensen ME, et al. Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol 2003; 95: 1005-1010.
24. Basaria S, Lieb J 2nd, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779-786.
25. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-1308.
26. Hamilton EJ, Gianatti E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377-383.
27. Galvao DA, Taaffe DR, Spry N, et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010; 28: 340-347.
28. Galvao DA, Nosaka K, Taaffe DR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006; 38: 2045-2052.
29. Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or Aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009; 27: 344-351.
30. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-2653.